Toxicology Studies
An increased incidence of benign pituitary tumors has been observed in male rats subjected to long-term repeated administration of Norade, a fact that is consistent with what has been previously observed. The situation is similar in rats after surgical castration, but no correlation with experience in humans has been found. In experiments on mice, after long-term repeated use of Norad at doses several times that commonly used in humans, proliferation of pancreatic islet cells and pyloric gastric mucosal cells was found. The clinical relevance of these facts is unclear.
Pharmacological effects
This drug is a synthetic analog of luteinizing hormone-releasing hormone. Long-term use can inhibit the secretion of luteinizing hormone in the pituitary gland, thereby causing male There is a decrease in serum testosterone and in women serum estradiol, an effect that is reversible after discontinuation of the drug.
In male patients, the testosterone concentration can be reduced to the post-castration level about 21 days after the first medication. During the treatment process of taking medication once every 28 days, the testosterone concentration has been maintained at the post-castration level. within the concentration range. This testosterone suppression effect causes prostate tumors to regress and symptoms to improve in most patients.
In female patients, the serum estradiol concentration is suppressed about 21 days after the initial treatment, and is maintained at postmenopausal levels every 28 days of treatment thereafter. This inhibition is associated with hormone-dependent breast cancer and endometriosis.
Indications
Prostate cancer and premenopausal and perimenopausal breast cancer that can be treated with hormones. It can also be used in the treatment of endometriosis, such as to relieve pain and reduce endometrial damage.
Yang Yan 22:34:16
You can call Nored’s sales hotline: 400-101-6868 (no long-distance charges), and a licensed pharmacist will answer your questions for free!